Aclaris Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Aclaris Therapeutics sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Aclaris Therapeutics: 33 sponsored US clinical trials, 1 recruiting.
Aclaris Therapeutics sponsors 33 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 28 completed. 8 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Common Wart, with 2 trials.
Top-decile sponsor footprint
Aclaris Therapeutics ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
33 total, page 1 of 1
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06585202
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
NCT05511519
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
NCT05432596
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
NCT05279417
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05216224
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
NCT04524858
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
NCT04598269
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
NCT04247815
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03812510
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03759340
Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03687372
A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03691831
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
NCT03585296
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
NCT03594227
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
NCT03551821
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
NCT03495817
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
NCT03487588
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
NCT03468855
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03315689
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
NCT03380390
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
NCT03354637
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
NCT03210337
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT03278028
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
NCT03224598
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
NCT03148691
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
NCT02667275
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
NCT02667236
An Open-Label Safety Study of A-101 Solution
NCT02667288
A Study of A-101 Solution in Subjects With Common Warts.
NCT02669862
Study of A-101 for the Treatment of Seborrheic Keratosis
NCT02260180
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
NCT02160626
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
NCT01986920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 24 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Aclaris Therapeutics pipeline
1 recruiting of 33 indexed (3% open); 28 completed (85%).
Phase mix: 8 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Common Wart (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Aclaris Therapeutics: open-pipeline peers nationwide
Peers matched on 33 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Aclaris Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 trials (± recruiting share)
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
- Centocor · 33 trials · 0% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Sarepta Therapeutics · 3% recruiting · 33 trials
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
Related
What to do with this Aclaris Therapeutics page
33 registered trials is a research-attention snapshot, not an endorsement of Aclaris Therapeutics or any single study.
- 1 of Aclaris Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Common Wart is the condition Aclaris Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Common Wart trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aclaris Therapeutics pipeline card: 33 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.